GHRP-2: Side Effects

Safety Notice#

The safety profile of GHRP-2 in humans is primarily characterized through its approved diagnostic use in Japan (as GHRP Kaken, administered as a single 100 mcg intravenous bolus) and from short-term clinical pharmacology studies. Long-term safety data from repeated administration are limited. The information below reflects available clinical and research data and should be interpreted in the context of these evidence limitations.

Reported Side Effects#

Overview of Adverse Effect Profile#

GHRP-2 is generally considered to have a favorable acute safety profile based on its diagnostic use in Japan and clinical pharmacology studies in healthy volunteers and patients with suspected GH deficiency. The most commonly reported effects are predictable consequences of its pharmacological mechanism: stimulation of GH release through GHS-R1a activation, with secondary effects on cortisol, prolactin, and appetite pathways.

Among the GHRP family, GHRP-2 is widely regarded as having the most balanced adverse effect profile, producing robust GH release with comparatively less stimulation of cortisol, prolactin, and aldosterone than hexarelin or GHRP-6. This selectivity advantage was a key factor in its selection as the diagnostic GHRP in Japan.

Increased Appetite#

Appetite stimulation is a predictable pharmacological consequence of GHS-R1a activation. The ghrelin receptor is expressed on hypothalamic neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons in the arcuate nucleus, and activation of these neurons by GHRP-2 shifts the hypothalamic energy balance toward increased hunger and food intake. In clinical studies, subjects receiving GHRP-2 have reported increased appetite and, when given access to food, consumed more calories than controls.

The appetite-stimulating effect of GHRP-2 is less pronounced than that of GHRP-6 or native ghrelin, reflecting its relatively more selective engagement of the GH-releasing pathway. The effect is typically transient, lasting 1-3 hours after administration, and is most noticeable with subcutaneous or intravenous dosing. In the diagnostic setting (single IV bolus), appetite changes are generally not clinically significant because the test is conducted in a fasting state.

Cortisol Elevation#

GHRP-2 produces a mild, transient elevation in serum cortisol levels following administration. This effect reflects stimulation of ACTH release from pituitary corticotrophs, likely through direct GHS-R1a activation on these cells or through hypothalamic CRH modulation. The cortisol increase is typically modest (20-40% above baseline) and returns to baseline within 1-2 hours.

The cortisol-stimulating effect of GHRP-2 is considerably less than that of hexarelin and somewhat less than that of GHRP-6. This relative selectivity is one of the pharmacological advantages of GHRP-2 over other GHRPs. In the diagnostic setting, the cortisol elevation is not considered clinically significant and does not interfere with GH measurement. With repeated daily administration in research protocols, the cumulative impact of mild cortisol stimulation on adrenal axis function has not been systematically evaluated.

Prolactin Elevation#

Mild transient prolactin elevation has been observed following GHRP-2 administration, though this effect is less consistent and less pronounced than the cortisol response. The mechanism is thought to involve GHS-R1a activation on lactotroph cells or modulation of dopaminergic inhibitory tone in the hypothalamus. The prolactin increase is typically less than 50% above baseline and normalizes within 1-2 hours.

GHRP-2 produces the least prolactin stimulation among the hexapeptide GHRPs. Hexarelin and GHRP-6 both cause more pronounced prolactin elevation. In clinical studies, GHRP-2-induced prolactin changes have not been associated with symptoms of hyperprolactinemia (galactorrhea, menstrual disturbance) at standard diagnostic or research doses.

Water Retention#

Mild water retention has been reported in some research contexts with repeated GHRP-2 administration. This effect is likely secondary to GH-stimulated sodium reabsorption in the kidneys and to IGF-1-mediated anti-natriuretic effects. The fluid retention is generally mild, manifesting as slight weight gain or peripheral edema, and resolves upon discontinuation.

Water retention is a class effect of GH elevation rather than a direct effect of GHRP-2 on fluid balance. It is more likely to be observed with protocols involving repeated daily dosing that produce sustained GH/IGF-1 elevation than with single diagnostic doses.

Flushing#

Transient facial flushing, warmth, and mild injection site reactions have been reported following intravenous GHRP-2 administration in the diagnostic setting. Flushing typically occurs within seconds to minutes of injection and resolves spontaneously within 5-10 minutes. The mechanism may involve local histamine release or vasoactive effects of peptide administration. The incidence and severity of flushing appear to be dose-dependent, with higher intravenous bolus doses producing more noticeable effects.

Additional Reported Effects#

Other effects reported in clinical studies include:

• Transient tingling or numbness: Occasionally reported at the extremities following IV administration; resolves spontaneously
• Mild dizziness or lightheadedness: Infrequently reported, possibly related to transient hemodynamic effects; self-limiting
• Injection site reactions: Redness, swelling, or discomfort at subcutaneous injection sites; standard for any peptide injection
• Transient changes in blood glucose: GH opposes insulin action; mild transient hyperglycemia may occur following GH release, though this is generally not clinically significant with single doses

Adverse Effect Comparison Across GHRPs#

Contraindications#

Pituitary Tumors#

GHRP-2 is contraindicated in individuals with known pituitary adenomas or other pituitary tumors. Stimulation of GH release through GHS-R1a activation could theoretically promote growth or hormonal hypersecretion from functioning pituitary tumors. In the diagnostic context, suspected pituitary tumor is a relative contraindication that requires clinical judgment regarding the risk-benefit ratio of the provocative test.

Active Cancer#

Chronic stimulation of the GH/IGF-1 axis is a theoretical concern in individuals with active malignancies. The GH-IGF-1 axis has proliferative and anti-apoptotic effects that could theoretically promote tumor growth. While GHRP-2 produces transient rather than sustained GH elevation, repeated use in individuals with active cancer is contraindicated as a precautionary measure. This concern applies to all GH secretagogues and to recombinant GH therapy.

Pregnancy#

GHRP-2 has not been studied in pregnant women, and no reproductive toxicology data are available. Given the absence of safety data and the theoretical risks of GH axis manipulation during pregnancy, use during pregnancy is contraindicated. Women of childbearing potential should be advised regarding this contraindication before diagnostic testing or research participation.

Additional Precautions#

• Diabetes mellitus: GH opposes insulin action; GHRP-2 may transiently worsen glycemic control, particularly in poorly controlled diabetes
• Hypopituitarism on replacement therapy: Interpretation of GHRP-2 stimulation test results may be affected by concurrent hormone replacement therapies
• Obesity: Baseline GH secretion is reduced in obesity, which may affect the magnitude of GH response to GHRP-2; diagnostic cutoff values may need adjustment for BMI
• Children: Pediatric use is established in the Japanese diagnostic context with appropriate dosing; safety in long-term pediatric use has not been evaluated

Drug Interactions#

GH/IGF-1 Axis Drugs#

Co-administration of GHRP-2 with recombinant human growth hormone (rhGH), IGF-1 (mecasermin), or GHRH analogs (tesamorelin, sermorelin) could produce additive or unpredictable effects on GH axis stimulation. In the diagnostic context, concurrent GH therapy should be discontinued for an appropriate washout period before GHRP-2 testing. GHRH-GHRP-2 synergy is intentionally exploited in some diagnostic protocols, but only under controlled clinical conditions.

Corticosteroids#

Exogenous glucocorticoids suppress the hypothalamic-pituitary-adrenal (HPA) axis and may blunt the cortisol response to GHRP-2. More importantly, chronic glucocorticoid use suppresses GH secretion and may reduce the GH response to GHRP-2, potentially confounding diagnostic test interpretation. The interaction is primarily pharmacodynamic rather than pharmacokinetic.

Insulin and Hypoglycemic Agents#

GH is a counter-regulatory hormone that opposes insulin action on glucose metabolism. GHRP-2-stimulated GH release may transiently reduce insulin sensitivity and elevate blood glucose. In individuals taking insulin or oral hypoglycemic agents, this interaction could theoretically alter glycemic control, though the transient nature of GHRP-2-induced GH elevation limits the clinical significance in most cases.

Somatostatin Analogs#

Somatostatin analogs (octreotide, lanreotide, pasireotide) directly suppress GH release from somatotrophs and are pharmacological antagonists of GHRP-2's GH-stimulatory action. Co-administration would be expected to attenuate or abolish the GH response to GHRP-2. This interaction is relevant for diagnostic testing in patients receiving somatostatin analog therapy for acromegaly or neuroendocrine tumors; washout periods are required for valid test results.

Other Potential Interactions#

• Dopamine agonists (cabergoline, bromocriptine): May modulate prolactin response to GHRP-2; potential for unpredictable effects on GH release through hypothalamic dopaminergic pathways
• Estrogens and oral contraceptives: Estrogen modulates GH secretory dynamics and may enhance the GH response to GHRP-2
• Beta-blockers: May blunt the GH response to some provocative stimuli, though the specific interaction with GHRP-2 has not been well characterized
• Opioids: Opioid drugs modulate GH secretion; potential for interaction with GHRP-2's neuroendocrine effects

Long-Term Safety Considerations#

The long-term safety profile of GHRP-2 with repeated administration remains poorly characterized. Key areas of uncertainty include:

• Tachyphylaxis and desensitization: Repeated daily dosing leads to progressive attenuation of the GH response, but the long-term consequences of chronic GHS-R1a stimulation on pituitary function are unknown
• Metabolic effects: Chronic GH/IGF-1 axis stimulation could affect glucose metabolism, body composition, and insulin sensitivity over time
• Oncological risk: Theoretical concern about long-term GH/IGF-1 axis elevation and cancer risk, based on epidemiological associations between IGF-1 levels and certain malignancies
• Adrenal function: Cumulative effects of repeated mild cortisol stimulation on HPA axis dynamics have not been evaluated
• Reproductive effects: Impact of chronic GHRP-2 use on reproductive hormone function is unknown

Evidence Gaps#

• The diagnostic safety profile is well characterized for single-dose IV administration (GHRP Kaken), but safety data for repeated subcutaneous dosing over weeks to months are limited
• Systematic adverse event monitoring from large populations has only been conducted in the Japanese diagnostic context
• Drug interaction studies are based on pharmacological reasoning rather than formal clinical interaction studies
• Long-term safety beyond the diagnostic setting has not been established through controlled clinical trials
• Population-specific safety data outside of Japanese populations are limited

Related Reading#

• GHRP-2 overview and research guide
• GHRP-2 dosing protocols
• GHRP-2 risks and legal status